Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 4:40 pm Sale | 2024-09-30 | 13G | Gossamer Bio, Inc. GOSS | Invus Public Equities, L.P. | 14,331,522 6.300% | -27,358![]() (-0.19%) | Filing History |
| 2024-11-12 4:31 pm Purchase | 2024-09-30 | 13G | Silence Therapeutics plc SLN | Invus Public Equities, L.P. | 8,495,310 6.100% | 156,453![]() (+1.88%) | Filing History |
| 2024-11-12 4:30 pm Purchase | 2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 3,651,201 9.900% | 82,359![]() (+2.31%) | Filing History |
| 2024-11-12 4:30 pm Sale | 2024-09-30 | 13G | GlycoMimetics, Inc. GLYC | Invus Public Equities, L.P. | 19,651 3.000% | -33,234![]() (-62.84%) | Filing History |
| 2024-09-26 4:30 pm Purchase | 2024-09-16 | 13G | Bicara Therapeutics Inc. Common Stock BCAX | Invus Public Equities, L.P. | 3,072,827 5.700% | 3,072,827![]() (New Position) | Filing History |
| 2024-08-15 5:01 pm Sale | 2024-08-13 | 13G | GlycoMimetics, Inc. GLYC | Invus Public Equities, L.P. | 52,885 8.200% | -33,006![]() (-38.43%) | Filing History |
| 2024-08-12 5:02 pm Purchase | 2024-08-01 | 13G | Vigil Neuroscience, Inc. VIGL | Invus Public Equities, L.P. | 1,991,038 5.300% | 1,991,038![]() (New Position) | Filing History |
| 2024-08-02 6:51 pm Purchase | 2024-07-25 | 13G | Silence Therapeutics plc SLN | Invus Public Equities, L.P. | 8,338,857 6.000% | 8,338,857![]() (New Position) | Filing History |
| 2024-08-02 6:41 pm Purchase | 2024-07-25 | 13G | IGM Biosciences, Inc. IGMS | Invus Public Equities, L.P. | 3,330,422 9.900% | 3,330,422![]() (New Position) | Filing History |
| 2024-08-02 6:39 pm Purchase | 2024-07-25 | 13G | Syros Pharmaceuticals, Inc. SYRS | Invus Public Equities, L.P. | 3,568,842 9.900% | 3,568,842![]() (New Position) | Filing History |
| 2024-08-02 6:38 pm Purchase | 2024-07-25 | 13G | HOOKIPA Pharma Inc. HOOK | Invus Public Equities, L.P. | 566,640 5.900% | 566,640![]() (New Position) | Filing History |
| 2024-08-02 6:37 pm Purchase | 2024-07-25 | 13G | Solid Biosciences Inc. SLDB | Invus Public Equities, L.P. | 2,508,143 6.500% | 2,508,143![]() (New Position) | Filing History |
| 2024-08-02 6:33 pm Purchase | 2024-07-25 | 13G | Seer, Inc. SEER | Invus Public Equities, L.P. | 4,195,185 6.900% | 4,195,185![]() (New Position) | Filing History |
| 2024-08-02 6:30 pm Purchase | 2024-07-25 | 13G | Gossamer Bio, Inc. GOSS | Invus Public Equities, L.P. | 14,358,880 6.300% | 14,358,880![]() (New Position) | Filing History |
| 2024-08-02 6:25 pm Purchase | 2024-07-25 | 13G | AlloVir, Inc. ALVR | Invus Public Equities, L.P. | 286,833 5.700% | 286,833![]() (New Position) | Filing History |
| 2024-07-29 7:27 pm Purchase | 2024-07-25 | 13G | Scholar Rock Holding Corporation SRRK | Invus Public Equities, L.P. | 12,834,446 15.800% | 12,834,446![]() (New Position) | Filing History |
| 2024-07-29 7:24 pm Purchase | 2024-07-25 | 13G | GlycoMimetics, Inc. GLYC | Invus Public Equities, L.P. | 85,891 13.300% | 85,891![]() (New Position) | Filing History |

